236 related articles for article (PubMed ID: 33500260)
1. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
Upadhyaya P; Lahdenranta J; Hurov K; Battula S; Dods R; Haines E; Kleyman M; Kristensson J; Kublin J; Lani R; Ma J; Mudd G; Repash E; Van Rietschoten K; Stephen T; You F; Harrison H; Chen L; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500260
[TBL] [Abstract][Full Text] [Related]
2. BT7480, a novel fully synthetic
Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.
Upadhyaya P; Kristensson J; Lahdenranta J; Repash E; Ma J; Kublin J; Mudd GE; Luus L; Jeffrey P; Hurov K; McDonnell K; Keen N
J Med Chem; 2022 Jul; 65(14):9858-9872. PubMed ID: 35819182
[TBL] [Abstract][Full Text] [Related]
4. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
6. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
7. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
8. A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
Sci Rep; 2019 Jul; 9(1):10862. PubMed ID: 31350431
[TBL] [Abstract][Full Text] [Related]
9. Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance.
Malyshkina A; Littwitz-Salomon E; Sutter K; Ross JA; Paschen A; Windmann S; Schimmer S; Dittmer U
Cancer Immunol Immunother; 2019 Mar; 68(3):479-488. PubMed ID: 30635687
[TBL] [Abstract][Full Text] [Related]
10. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
11. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M
Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872
[TBL] [Abstract][Full Text] [Related]
12. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
13. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
[TBL] [Abstract][Full Text] [Related]
14. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
15. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
17. Direct CD137 costimulation of CD8 T cells promotes retention and innate-like function within nascent atherogenic foci.
Xu MM; Ménoret A; Nicholas SE; Günther S; Sundberg EJ; Zhou B; Rodriguez A; Murphy PA; Vella AT
Am J Physiol Heart Circ Physiol; 2019 Jun; 316(6):H1480-H1494. PubMed ID: 30978132
[TBL] [Abstract][Full Text] [Related]
18. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
19. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
20. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
Dubrot J; Milheiro F; Alfaro C; Palazón A; Martinez-Forero I; Perez-Gracia JL; Morales-Kastresana A; Romero-Trevejo JL; Ochoa MC; Hervás-Stubbs S; Prieto J; Jure-Kunkel M; Chen L; Melero I
Cancer Immunol Immunother; 2010 Aug; 59(8):1223-33. PubMed ID: 20336294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
